Frontotemporal dementia (FTD) is a clinical, genetic, and pathologic heterogeneous group of neurodegenerative diseases. In this study, we investigated the role of APOƐ4, rs5848 in GRN, and rs1042522 in TP53 gene as disease risk factors and/or phenotype modifiers in 440 FTD patients, including 175 C9orf72 expansion carriers. We found that the C9orf72 expansion carriers showing an earlier age at onset (p < 0.001). Among the clinical groups, the FTD-MND (motoneuron disease) showed the lowest survival (hazard ratio [HR] = 4.12), and the progressive nonfluent aphasia group showed the highest onset age (p = 0.03). In our cohort, the rs1042522 in TP53 was associated with disease onset (p = 0.02) and survival (HR = 1.73) and rs5848 GRN with a significantly shorter survival in CC homozygous patients (HR = 1.98). The frequency of APOƐ4 carriers was significantly increased in the C9orf72 noncarriers (p = 0.022). Although validation of our findings is necessary, our results suggest that TP53, GRN, and APOE genes may act as phenotype modifiers in FTD and should be considered in future clinical trials.

Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia / I. Rosas, C. Martinez, E. Coto, J. Clarimon, A. Lleo, I. Illan-Gala, O. Dols-Icardo, B. Borroni, M.R. Almeida, J. van der Zee, C. Van Broeckhoven, A.C. Bruni, M. Anfossi, L. Bernardi, R. Maletta, M. Serpente, D. Galimberti, E. Scarpini, G. Rossi, P. Caroppo, L. Benussi, R. Ghidoni, G. Binetti, B. Nacmias, S. Sorbi, I. Piaceri, S. Bagnoli, A. Antonell, R. Sanchez-Valle, B. De la Casa-Fages, F. Grandas, M. Diez-Fairen, P. Pastor, R. Ferrari, D. Queimalinos-Perez, S. Perez-Oliveira, V. Alvarez, M. Menendez-Gonzalez. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 99(2021 Mar), pp. e15-e22. [10.1016/j.neurobiolaging.2020.08.018]

Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia

M. Serpente;D. Galimberti;E. Scarpini;
2021

Abstract

Frontotemporal dementia (FTD) is a clinical, genetic, and pathologic heterogeneous group of neurodegenerative diseases. In this study, we investigated the role of APOƐ4, rs5848 in GRN, and rs1042522 in TP53 gene as disease risk factors and/or phenotype modifiers in 440 FTD patients, including 175 C9orf72 expansion carriers. We found that the C9orf72 expansion carriers showing an earlier age at onset (p < 0.001). Among the clinical groups, the FTD-MND (motoneuron disease) showed the lowest survival (hazard ratio [HR] = 4.12), and the progressive nonfluent aphasia group showed the highest onset age (p = 0.03). In our cohort, the rs1042522 in TP53 was associated with disease onset (p = 0.02) and survival (HR = 1.73) and rs5848 GRN with a significantly shorter survival in CC homozygous patients (HR = 1.98). The frequency of APOƐ4 carriers was significantly increased in the C9orf72 noncarriers (p = 0.022). Although validation of our findings is necessary, our results suggest that TP53, GRN, and APOE genes may act as phenotype modifiers in FTD and should be considered in future clinical trials.
Frontotemporal dementia; Age at onset; Survival probability; TP53; GRN; APOE
Settore BIO/13 - Biologia Applicata
Settore MED/26 - Neurologia
mar-2021
2-set-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0197458020302748-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 596.83 kB
Formato Adobe PDF
596.83 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/771622
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact